{"gene":"SLC6A1","run_date":"2026-06-10T07:46:34","timeline":{"discoveries":[{"year":2025,"finding":"Pathogenic SLC6A1 variants strongly reduce GAT-1-mediated GABA uptake (mean –89.4%), as measured by a fluorescence-based iGABA-Snfr sensor assay; variant-specific uptake reductions were highly correlated with radioactive [3H]-GABA uptake results (R²=0.8095). The molecular chaperone 4-phenylbutyric acid (4PBA) increased GAT-1-mediated GABA uptake by ~35%.","method":"High-content fluorescence imaging assay using genetically encoded GABA sensor (iGABA-Snfr) in cells expressing SLC6A1 variants; validated against radioactive [3H]-GABA uptake assay","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — functional uptake assay with two orthogonal methods (fluorescent sensor and radioactive uptake), single lab, multiple variants tested with strong correlation between methods","pmids":["bio_10.1101_2025.11.06.687003"],"is_preprint":true},{"year":2025,"finding":"SLC6A1 haploinsufficiency results in a partial loss-of-function mechanism; a Drosophila allelic series confirmed that missense variants (including p.A334S) cause hypomorphic phenotypes consistent with reduced GAT-1 activity, with clinical severity correlating with degree of functional loss.","method":"Drosophila melanogaster allelic series expressing SLC6A1 variants; phenotypic characterization of motor and neurological phenotypes","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo model organism loss-of-function with defined phenotypic readout, single lab, ortholog-based functional validation","pmids":["bio_10.1101_2024.09.27.24314092"],"is_preprint":true},{"year":2025,"finding":"SLC6A1 deficiency in human MGE organoids causes a migration deficit of MGE-derived interneurons when fused with cortical organoids, indicating a cell-autonomous role for GAT-1 in interneuron migration during development.","method":"hPSC-derived MGE organoids fused with cortical organoids; transcriptomic analysis and electrophysiology; SLC6A1 loss-of-function disease model","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — human organoid model with defined cellular phenotype (migration deficit), single lab, single method for the migration readout","pmids":["bio_10.1101_2025.07.01.662594"],"is_preprint":true},{"year":2025,"finding":"SLC6A1 genotypes with reduced GAT1 transporter activity are quantitatively linked to epilepsy severity and intellectual disability, with functionally validated SLC6A1 variants showing loss of GABA reuptake activity.","method":"Functional validation of SLC6A1 variants by GABA uptake assays; correlation of transporter activity with clinical severity in a cohort of 708 individuals","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional uptake assay with quantitative correlation to clinical phenotype, multi-center cohort, single method type for transporter activity","pmids":["bio_10.1101_2025.04.01.24316792"],"is_preprint":true},{"year":2025,"finding":"Smarcc2 deficiency in mouse prefrontal cortex reduces histone acetylation (H3K9ac) at the Slc6a1 (GAT1) promoter, leading to downregulation of Slc6a1 expression and impaired GABAergic synaptic currents; this was rescued by the HDAC inhibitor romidepsin.","method":"ChIP-seq for H3K9ac at Slc6a1 promoter; RNA-seq and qPCR in Smarcc2-deficient mouse PFC; electrophysiological recordings of GABAergic currents; romidepsin rescue experiment","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (ChIP-seq, RNA-seq, electrophysiology, pharmacological rescue), single lab","pmids":["bio_10.1101_2025.05.29.656867"],"is_preprint":true},{"year":2024,"finding":"Proteochemometric modeling identified amino acid Q299 (in BGT1 numbering; corresponding position in GAT1 is L300) as relevant for ligand binding and subtype selectivity among GABA transporter subtypes (GAT1/BGT1/GAT2/GAT3).","method":"Proteochemometric modeling (partial least squares and random forest) using dataset of 323 compounds with bioactivity data across four GABA transporter subtypes; protein descriptor importance analysis","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 4 / Weak — computational prediction only, no experimental mutagenesis or binding validation performed","pmids":["bio_10.1101_2024.08.13.607728"],"is_preprint":true}],"current_model":"SLC6A1 encodes GAT-1 (GABA Transporter 1), a plasma membrane GABA reuptake transporter whose loss-of-function—through pathogenic missense, nonsense, or haploinsufficiency variants—reduces presynaptic GABA reuptake, with severity quantitatively correlated to residual transporter activity; GAT-1 expression at the promoter level is regulated by SMARCC2-dependent histone acetylation, and GAT-1 function is partially rescued by the molecular chaperone 4-PBA, while SLC6A1 deficiency also impairs interneuron migration during cortical development."},"narrative":{"mechanistic_narrative":"SLC6A1 encodes GAT-1, a plasma membrane GABA reuptake transporter whose principal disease mechanism is partial loss of transporter function: pathogenic variants strongly reduce GAT-1-mediated GABA uptake (mean −89.4%), and residual transporter activity correlates quantitatively with epilepsy severity and intellectual disability across patient cohorts [PMID:bio_10.1101_2025.11.06.687003, PMID:bio_10.1101_2025.04.01.24316792]. A Drosophila allelic series confirms that missense variants such as p.A334S act as hypomorphs producing graded neurological phenotypes, establishing haploinsufficiency with severity scaling to functional loss [PMID:bio_10.1101_2024.09.27.24314092]. Beyond its synaptic reuptake role, GAT-1 is required cell-autonomously for migration of MGE-derived interneurons during cortical development, as shown in fused human organoid models [PMID:bio_10.1101_2025.07.01.662594]. SLC6A1 expression is set transcriptionally through SMARCC2-dependent H3K9 acetylation at its promoter, and the molecular chaperone 4-phenylbutyric acid partially restores uptake by deficient transporters [PMID:bio_10.1101_2025.11.06.687003, PMID:bio_10.1101_2025.05.29.656867].","teleology":[{"year":2024,"claim":"Computational modeling sought to define which transporter residues govern ligand binding and selectivity among GABA transporter subtypes, addressing the basis of subtype-specific pharmacology.","evidence":"Proteochemometric modeling across four GABA transporter subtypes using 323 compounds with descriptor importance analysis","pmids":["bio_10.1101_2024.08.13.607728"],"confidence":"Low","gaps":["Computational prediction only; no experimental mutagenesis or binding validation","Identified position is in BGT1 numbering, not directly tested in GAT-1","No functional consequence for human variants established"]},{"year":2025,"claim":"To define the disease mechanism, functional assays asked whether pathogenic SLC6A1 variants impair GABA uptake and whether activity could be pharmacologically restored, establishing loss-of-function with a candidate therapeutic correction.","evidence":"iGABA-Snfr fluorescence sensor uptake assay cross-validated against [3H]-GABA uptake in cells expressing variants, plus 4PBA rescue","pmids":["bio_10.1101_2025.11.06.687003"],"confidence":"Medium","gaps":["Single lab; cell-based overexpression rather than endogenous context","4PBA rescue mechanism (chaperone-mediated trafficking) not directly demonstrated","Not all variant classes covered by the same readout"]},{"year":2025,"claim":"An in vivo allelic series tested whether SLC6A1 acts through haploinsufficiency and whether clinical severity tracks residual activity, confirming a graded hypomorphic mechanism.","evidence":"Drosophila allelic series expressing human variants with motor/neurological phenotyping","pmids":["bio_10.1101_2024.09.27.24314092"],"confidence":"Medium","gaps":["Ortholog-based model; mammalian validation of individual variants not shown","Single lab","Quantitative mapping of fly phenotype to human severity indirect"]},{"year":2025,"claim":"A multi-center cohort connected functionally measured transporter activity to clinical outcome, establishing a genotype-function-phenotype quantitative relationship.","evidence":"GABA uptake functional validation correlated with epilepsy severity and intellectual disability in 708 individuals","pmids":["bio_10.1101_2025.04.01.24316792"],"confidence":"Medium","gaps":["Single assay type for transporter activity","Correlation does not isolate other genetic modifiers","Mechanistic link between reuptake loss and ID not resolved"]},{"year":2025,"claim":"Organoid modeling asked whether GAT-1 has a developmental role beyond synaptic reuptake, revealing a cell-autonomous requirement for interneuron migration.","evidence":"hPSC-derived MGE organoids fused with cortical organoids, transcriptomics and electrophysiology under SLC6A1 loss-of-function","pmids":["bio_10.1101_2025.07.01.662594"],"confidence":"Medium","gaps":["Single method for the migration readout","Molecular mechanism coupling GAT-1 to migration unknown","Not validated in vivo"]},{"year":2025,"claim":"Chromatin profiling identified an upstream transcriptional regulator of SLC6A1, showing that SMARCC2-dependent histone acetylation controls GAT-1 expression and GABAergic transmission.","evidence":"H3K9ac ChIP-seq at Slc6a1 promoter, RNA-seq/qPCR, GABAergic current recordings, and romidepsin rescue in Smarcc2-deficient mouse PFC","pmids":["bio_10.1101_2025.05.29.656867"],"confidence":"Medium","gaps":["Demonstrated in mouse PFC; human relevance inferred","Direct vs indirect SMARCC2 action at the promoter not fully resolved","Single lab"]},{"year":null,"claim":"How loss of GAT-1 GABA reuptake mechanistically produces intellectual disability, and the molecular pathway linking GAT-1 to interneuron migration, remain undefined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of human GAT-1 variant effects experimentally validated","Migration mechanism unexplained","Therapeutic durability of 4PBA/chaperone rescue untested in vivo"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,1,3]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[2,4]}],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P30531","full_name":"Sodium- and chloride-dependent GABA transporter 1","aliases":["Solute carrier family 6 member 1"],"length_aa":599,"mass_kda":67.1,"function":"Mediates transport of gamma-aminobutyric acid (GABA) together with sodium and chloride and is responsible for the reuptake of GABA from the synapse (PubMed:30132828). The translocation of GABA, however, may also occur in the reverse direction leading to the release of GABA (By similarity). The direction and magnitude of GABA transport is a consequence of the prevailing thermodynamic conditions, determined by membrane potential and the intracellular and extracellular concentrations of Na(+), Cl(-) and GABA (By similarity). Can also mediate sodium- and chloride-dependent transport of hypotaurine but to a much lower extent as compared to GABA (By similarity)","subcellular_location":"Cell membrane; Presynapse","url":"https://www.uniprot.org/uniprotkb/P30531/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SLC6A1","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SLC6A1","total_profiled":1310},"omim":[{"mim_id":"618443","title":"NEURODEVELOPMENTAL DISORDER WITH OR WITHOUT VARIABLE BRAIN ABNORMALITIES; NEDBA","url":"https://www.omim.org/entry/618443"},{"mim_id":"616421","title":"MYOCLONIC-ATONIC EPILEPSY; MAE","url":"https://www.omim.org/entry/616421"},{"mim_id":"607952","title":"SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, GABA), MEMBER 11; SLC6A11","url":"https://www.omim.org/entry/607952"},{"mim_id":"600131","title":"EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 1; ECA1","url":"https://www.omim.org/entry/600131"},{"mim_id":"137165","title":"SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, GABA), MEMBER 1; SLC6A1","url":"https://www.omim.org/entry/137165"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":85.6},{"tissue":"liver","ntpm":82.4},{"tissue":"retina","ntpm":34.6}],"url":"https://www.proteinatlas.org/search/SLC6A1"},"hgnc":{"alias_symbol":["GAT1","GABATR","GABATHG","GAT-1","hGAT-1"],"prev_symbol":[]},"alphafold":{"accession":"P30531","domains":[{"cath_id":"1.20.1740.10","chopping":"50-570","consensus_level":"high","plddt":94.0157,"start":50,"end":570}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P30531","model_url":"https://alphafold.ebi.ac.uk/files/AF-P30531-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P30531-F1-predicted_aligned_error_v6.png","plddt_mean":87.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SLC6A1","jax_strain_url":"https://www.jax.org/strain/search?query=SLC6A1"},"sequence":{"accession":"P30531","fasta_url":"https://rest.uniprot.org/uniprotkb/P30531.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P30531/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P30531"}},"corpus_meta":[{"pmid":null,"id":"bio_10.1101_2025.11.06.687003","title":"High-throughput imaging of GABA fluorescence as a functional assay for variants in the neurodevelopmental gene,  <i>SLC6A1</i>","date":"2025-11-07","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.06.687003","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.01.24316792","title":"Pathogenic ultra-rare variants in<i>SLC6A1, SLC6A11, GAD1 and GAD2</i>are new & recurrent GABAergic loci for GGE syndromes","date":"2025-04-04","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.01.24316792","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.29.656867","title":"Cognitive and Synaptic Impairment Induced by Deficiency of Autism Risk Gene  <i>Smarcc2</i>  and its Rescue by Histone Deacetylase Inhibition","date":"2025-05-30","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.29.656867","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.13.607728","title":"Proteochemometric modeling strengthens the role of Q299 for GABA transporter subtype selectivity","date":"2024-08-16","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.13.607728","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.11.19.689106","title":"Immature  <i>C. elegans</i>  motor neurons control early embryo behavior via both synaptic and non-synaptic GABA release","date":"2025-11-19","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.19.689106","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.01.662594","title":"Human Medial Ganglionic Eminence Organoids Robustly Generate Parvalbumin Interneurons and Fast-Spiking Neurons and Reveal Migratory Deficits in SLC6A1 Deficient Interneurons","date":"2025-07-04","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.01.662594","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.14.24314843","title":"Analysis of exome sequencing data implicates rare coding variants in<i>STAG1</i>and<i>ZNF136</i>in schizophrenia","date":"2024-10-16","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.14.24314843","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.06.24316676","title":"4-Phenylbutyrate for STXBP1 and SLC6A1. Safety, tolerability, seizure, and EEG outcomes. A case series at 2 centers","date":"2024-11-08","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.06.24316676","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.27.24314092","title":"Resolution of<i>SLC6A1</i>variable expressivity in a multi-generational family using deep clinical phenotyping and<i>Drosophila</i>models","date":"2024-09-28","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.27.24314092","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.25.645215","title":"Identification and characterization of potent and selective inhibitors for the B  <sup>0</sup>  AT2/SLC6A15 amino acid transporter","date":"2025-03-25","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.25.645215","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.04.602053","title":"Evidence for low affinity of GABA at the vesicular monoamine transporter VMAT2 – implications for transmitter co-release from dopamine neurons","date":"2024-07-08","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.04.602053","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.27.25320972","title":"Enhancing Rare Disease Education through AI-Driven Podcast Generation","date":"2025-01-28","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.27.25320972","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.13.612874","title":"Glial alterations in the glutamatergic and GABAergic signaling pathways in a mouse model of Lafora disease, a severe form of progressive myoclonus epilepsy","date":"2024-09-15","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.13.612874","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.06.27.24309590","title":"A unified meta-regression model identifies genes associated with epilepsy","date":"2024-06-28","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.27.24309590","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":10569,"output_tokens":1650,"usd":0.028229,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8414,"output_tokens":2270,"usd":0.04941,"stage2_stop_reason":"end_turn"},"total_usd":0.077639,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2025,\n      \"finding\": \"Pathogenic SLC6A1 variants strongly reduce GAT-1-mediated GABA uptake (mean –89.4%), as measured by a fluorescence-based iGABA-Snfr sensor assay; variant-specific uptake reductions were highly correlated with radioactive [3H]-GABA uptake results (R²=0.8095). The molecular chaperone 4-phenylbutyric acid (4PBA) increased GAT-1-mediated GABA uptake by ~35%.\",\n      \"method\": \"High-content fluorescence imaging assay using genetically encoded GABA sensor (iGABA-Snfr) in cells expressing SLC6A1 variants; validated against radioactive [3H]-GABA uptake assay\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — functional uptake assay with two orthogonal methods (fluorescent sensor and radioactive uptake), single lab, multiple variants tested with strong correlation between methods\",\n      \"pmids\": [\"bio_10.1101_2025.11.06.687003\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SLC6A1 haploinsufficiency results in a partial loss-of-function mechanism; a Drosophila allelic series confirmed that missense variants (including p.A334S) cause hypomorphic phenotypes consistent with reduced GAT-1 activity, with clinical severity correlating with degree of functional loss.\",\n      \"method\": \"Drosophila melanogaster allelic series expressing SLC6A1 variants; phenotypic characterization of motor and neurological phenotypes\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo model organism loss-of-function with defined phenotypic readout, single lab, ortholog-based functional validation\",\n      \"pmids\": [\"bio_10.1101_2024.09.27.24314092\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SLC6A1 deficiency in human MGE organoids causes a migration deficit of MGE-derived interneurons when fused with cortical organoids, indicating a cell-autonomous role for GAT-1 in interneuron migration during development.\",\n      \"method\": \"hPSC-derived MGE organoids fused with cortical organoids; transcriptomic analysis and electrophysiology; SLC6A1 loss-of-function disease model\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — human organoid model with defined cellular phenotype (migration deficit), single lab, single method for the migration readout\",\n      \"pmids\": [\"bio_10.1101_2025.07.01.662594\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SLC6A1 genotypes with reduced GAT1 transporter activity are quantitatively linked to epilepsy severity and intellectual disability, with functionally validated SLC6A1 variants showing loss of GABA reuptake activity.\",\n      \"method\": \"Functional validation of SLC6A1 variants by GABA uptake assays; correlation of transporter activity with clinical severity in a cohort of 708 individuals\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional uptake assay with quantitative correlation to clinical phenotype, multi-center cohort, single method type for transporter activity\",\n      \"pmids\": [\"bio_10.1101_2025.04.01.24316792\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Smarcc2 deficiency in mouse prefrontal cortex reduces histone acetylation (H3K9ac) at the Slc6a1 (GAT1) promoter, leading to downregulation of Slc6a1 expression and impaired GABAergic synaptic currents; this was rescued by the HDAC inhibitor romidepsin.\",\n      \"method\": \"ChIP-seq for H3K9ac at Slc6a1 promoter; RNA-seq and qPCR in Smarcc2-deficient mouse PFC; electrophysiological recordings of GABAergic currents; romidepsin rescue experiment\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (ChIP-seq, RNA-seq, electrophysiology, pharmacological rescue), single lab\",\n      \"pmids\": [\"bio_10.1101_2025.05.29.656867\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Proteochemometric modeling identified amino acid Q299 (in BGT1 numbering; corresponding position in GAT1 is L300) as relevant for ligand binding and subtype selectivity among GABA transporter subtypes (GAT1/BGT1/GAT2/GAT3).\",\n      \"method\": \"Proteochemometric modeling (partial least squares and random forest) using dataset of 323 compounds with bioactivity data across four GABA transporter subtypes; protein descriptor importance analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — computational prediction only, no experimental mutagenesis or binding validation performed\",\n      \"pmids\": [\"bio_10.1101_2024.08.13.607728\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"SLC6A1 encodes GAT-1 (GABA Transporter 1), a plasma membrane GABA reuptake transporter whose loss-of-function—through pathogenic missense, nonsense, or haploinsufficiency variants—reduces presynaptic GABA reuptake, with severity quantitatively correlated to residual transporter activity; GAT-1 expression at the promoter level is regulated by SMARCC2-dependent histone acetylation, and GAT-1 function is partially rescued by the molecular chaperone 4-PBA, while SLC6A1 deficiency also impairs interneuron migration during cortical development.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SLC6A1 encodes GAT-1, a plasma membrane GABA reuptake transporter whose principal disease mechanism is partial loss of transporter function: pathogenic variants strongly reduce GAT-1-mediated GABA uptake (mean −89.4%), and residual transporter activity correlates quantitatively with epilepsy severity and intellectual disability across patient cohorts [#0, #3]. A Drosophila allelic series confirms that missense variants such as p.A334S act as hypomorphs producing graded neurological phenotypes, establishing haploinsufficiency with severity scaling to functional loss [#1]. Beyond its synaptic reuptake role, GAT-1 is required cell-autonomously for migration of MGE-derived interneurons during cortical development, as shown in fused human organoid models [#2]. SLC6A1 expression is set transcriptionally through SMARCC2-dependent H3K9 acetylation at its promoter, and the molecular chaperone 4-phenylbutyric acid partially restores uptake by deficient transporters [#0, #4].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2024,\n      \"claim\": \"Computational modeling sought to define which transporter residues govern ligand binding and selectivity among GABA transporter subtypes, addressing the basis of subtype-specific pharmacology.\",\n      \"evidence\": \"Proteochemometric modeling across four GABA transporter subtypes using 323 compounds with descriptor importance analysis\",\n      \"pmids\": [\"bio_10.1101_2024.08.13.607728\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Computational prediction only; no experimental mutagenesis or binding validation\", \"Identified position is in BGT1 numbering, not directly tested in GAT-1\", \"No functional consequence for human variants established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"To define the disease mechanism, functional assays asked whether pathogenic SLC6A1 variants impair GABA uptake and whether activity could be pharmacologically restored, establishing loss-of-function with a candidate therapeutic correction.\",\n      \"evidence\": \"iGABA-Snfr fluorescence sensor uptake assay cross-validated against [3H]-GABA uptake in cells expressing variants, plus 4PBA rescue\",\n      \"pmids\": [\"bio_10.1101_2025.11.06.687003\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; cell-based overexpression rather than endogenous context\", \"4PBA rescue mechanism (chaperone-mediated trafficking) not directly demonstrated\", \"Not all variant classes covered by the same readout\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"An in vivo allelic series tested whether SLC6A1 acts through haploinsufficiency and whether clinical severity tracks residual activity, confirming a graded hypomorphic mechanism.\",\n      \"evidence\": \"Drosophila allelic series expressing human variants with motor/neurological phenotyping\",\n      \"pmids\": [\"bio_10.1101_2024.09.27.24314092\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ortholog-based model; mammalian validation of individual variants not shown\", \"Single lab\", \"Quantitative mapping of fly phenotype to human severity indirect\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A multi-center cohort connected functionally measured transporter activity to clinical outcome, establishing a genotype-function-phenotype quantitative relationship.\",\n      \"evidence\": \"GABA uptake functional validation correlated with epilepsy severity and intellectual disability in 708 individuals\",\n      \"pmids\": [\"bio_10.1101_2025.04.01.24316792\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single assay type for transporter activity\", \"Correlation does not isolate other genetic modifiers\", \"Mechanistic link between reuptake loss and ID not resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Organoid modeling asked whether GAT-1 has a developmental role beyond synaptic reuptake, revealing a cell-autonomous requirement for interneuron migration.\",\n      \"evidence\": \"hPSC-derived MGE organoids fused with cortical organoids, transcriptomics and electrophysiology under SLC6A1 loss-of-function\",\n      \"pmids\": [\"bio_10.1101_2025.07.01.662594\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single method for the migration readout\", \"Molecular mechanism coupling GAT-1 to migration unknown\", \"Not validated in vivo\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Chromatin profiling identified an upstream transcriptional regulator of SLC6A1, showing that SMARCC2-dependent histone acetylation controls GAT-1 expression and GABAergic transmission.\",\n      \"evidence\": \"H3K9ac ChIP-seq at Slc6a1 promoter, RNA-seq/qPCR, GABAergic current recordings, and romidepsin rescue in Smarcc2-deficient mouse PFC\",\n      \"pmids\": [\"bio_10.1101_2025.05.29.656867\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Demonstrated in mouse PFC; human relevance inferred\", \"Direct vs indirect SMARCC2 action at the promoter not fully resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How loss of GAT-1 GABA reuptake mechanistically produces intellectual disability, and the molecular pathway linking GAT-1 to interneuron migration, remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of human GAT-1 variant effects experimentally validated\", \"Migration mechanism unexplained\", \"Therapeutic durability of 4PBA/chaperone rescue untested in vivo\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 1, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [2, 4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win"}}